Non-leukoreduced Red Blood Cells Versus Whole Blood Transfusion: Implications for Cytomegalovirus Reactivation in Sickle Cell Patients
Tanzania Journal of Health Research · 2026 · 27 (4) · 3802-3813
DOI: 10.4314/thrb.v27i4.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tanzania Journal of Health Research, 2026. Verfasst von Avelina Paschal Mgasa und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterised by the production of haemoglobin S, leading to anaemia and frequent transfusions. Ensuring transfusion safety in many low-resource settings remains difficult due to the high prevalence of transfusion-transmissible infections, including cytomegalovirus (CMV), which is often not screened for in donor blood, and to the rare use of leukoreduction.
Objectives
This study aimed to determine whether CMV reactivation in SCD patients is associated with a specific transfusion protocol.
Methods
We performed cross sectional study to compared CMV-specific immunoglobulin M (IgM) levels (measured by ELISA) in SCD patients attending two hospitals (Temeke Regional Referral Hospital and Muhimbili National Hospital) in Dar es Salaam, Tanzania, that use different transfusion protocols: non-leukoreduced whole blood versus non-leukoreduced red cell component transfusion, respectively. A total of 455 SCD patients who attended between July 2023 and March 2024 were enrolled and tested for CMV antibodies.
Results
Patients receiving non-leukoreduced whole blood transfusions showed significantly higher CMV-specific IgM titers, indicating recent CMV infection or reactivation. Additionally, SCD patients who had received non-leukoreduced red blood cell transfusions and had laboratory test prescriptions showed elevated CMV-specific IgM titers, and specifically, those who had at least one transfusion episode had a significantly lower monocyte-to-lymphocyte ratio.
Conclusion
These results suggest that CMV infection or reactivation was more prevalent among patients who received non-leukoreduced whole blood. Our results emphasise the importance of prioritising blood component transfusions and implementing routine CMV monitoring to enhance transfusion safety in patients with SCD in endemic regions.
Zitieren
APA
Mgasa, A. P., Ernest, W., Yonazi, M., Maeda, D., & Marandu, T. (2026). Non-leukoreduced Red Blood Cells Versus Whole Blood Transfusion: Implications for Cytomegalovirus Reactivation in Sickle Cell Patients. Tanzania Journal of Health Research, 27(4), 3802-3813. https://doi.org/10.4314/thrb.v27i4.9
Vancouver
Mgasa AP, Ernest W, Yonazi M, Maeda D, Marandu T. Non-leukoreduced Red Blood Cells Versus Whole Blood Transfusion: Implications for Cytomegalovirus Reactivation in Sickle Cell Patients. Tanzania Journal of Health Research. 2026;27(4):3802-3813. doi:10.4314/thrb.v27i4.9
BibTeX
@article{Mgasa2026,
author = {Mgasa, Avelina Paschal and Ernest, Winnie and Yonazi, Mbonea and Maeda, Daniel and Marandu, Thomas},
title = {Non-leukoreduced Red Blood Cells Versus Whole Blood Transfusion: Implications for Cytomegalovirus Reactivation in Sickle Cell Patients},
journal = {Tanzania Journal of Health Research},
year = {2026},
volume = {27},
number = {4},
pages = {3802--3813},
doi = {10.4314/thrb.v27i4.9}
}
EUVIMED